BIOCRYST PHARMACEUTICALS INC. - COMMON STOCK

BioCryst Announces ORLADEYO® (berotralstat) Data to be Presented at European Academy of Allergy and Clinical Immunology (EAACI) Hybrid Congress 2022

22 6 2022 07:00:02 提供 Nasdaq GlobeNewswire

BioCryst Selects Pint Pharma as Commercial Partner for ORLADEYO® (berotralstat) in Latin America

09 6 2022 07:00:00 提供 Nasdaq GlobeNewswire

FDA Grants Fast Track Designation for BioCryst’s ALK-2 Inhibitor, BCX9250

08 6 2022 07:00:01 提供 Nasdaq GlobeNewswire

BioCryst Announces Approval of ORLADEYO® (berotralstat) by Swissmedic

07 6 2022 09:00:02 提供 Nasdaq GlobeNewswire

BioCryst Announces Health Canada has Authorized ORLADEYO® (berotralstat), the Only Oral Treatment for the Prevention of Hereditary Angioedema Attacks

06 6 2022 07:00:30 提供 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

01 6 2022 07:00:15 提供 Nasdaq GlobeNewswire

BioCryst to Present at Upcoming Investor Conferences

06 5 2022 07:00:28 提供 Nasdaq GlobeNewswire

BioCryst Reports First Quarter 2022 Financial Results and Upcoming Key Milestones

05 5 2022 07:00:11 提供 Nasdaq GlobeNewswire

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

04 5 2022 16:15:39 提供 Nasdaq GlobeNewswire

European Medicines Agency Grants PRIME Designation to BioCryst’s ALK-2 Inhibitor, BCX9250, for Treatment of Fibrodysplasia Ossificans Progressiva

27 4 2022 07:00:00 提供 Nasdaq GlobeNewswire